Who is sponsoring CP/CPPS?

CP/CPPS is sponsored by Aquinox Pharmaceuticals (Canada) Inc..

What condition does CP/CPPS study?

CP/CPPS studies Chronic Prostatitis, Chronic Pelvic Pain Syndrome.

What drugs are being tested in CP/CPPS?

Interventions: AQX-1125 200 mg, Placebo.

What is the status of CP/CPPS?

CP/CPPS is currently TERMINATED.

Last reviewed 2019-01-09 · How we verify

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT03500159 PHASE2 TERMINATED Results posted

This is a randomized, multi-center, double-blind, parallel-group study, enrolling approximately 100 male subjects diagnosed with CP/CPPS to evaluate the effect of 12-week treatment with AQX-1125 (active drug) compared to placebo. The subjects will be randomized to receive orally once-daily either AQX-1125 (200 mg) or placebo in a 1:1 ratio across approximately 30 centers in North America (United States and Canada). The study will consist of a screening period of up to 3 weeks, a 12-week treatment period followed by a 4-week off drug safety follow-up period, and an ophthalmic safety follow-up call at 3 months and visit at 6 months post last dose, for a total study duration of about 41 weeks.

Details

Lead sponsor	Aquinox Pharmaceuticals (Canada) Inc.
Phase	PHASE2
Status	TERMINATED
Enrolment	3
Start date	Wed Apr 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Chronic Prostatitis
Chronic Pelvic Pain Syndrome

Interventions

AQX-1125 200 mg
Placebo

Countries

Canada, United States